Short answer · Medically reviewed summary · Last updated: 2026-05-08
Pars planitis is a chronic form of intermediate uveitis characterized by inflammation of the pars plana, the area between the iris and the retina. First formally described in the 1950s, the condition has evolved from a mysterious ocular ailment into a recognized autoimmune-mediated entity, with 21 individuals currently sharing their lived experiences through the DiseaseMaps.org community. When was Pars Planitis first identified? While clinicians had observed peripheral retinal inflammation for decades, the specific entity known as pars planitis was first clearly characterized in 1950 by Dr.
What is the history of Pars Planitis?
History of Pars Planitis: when and how it was discovered, and the milestones in research since, medically reviewed.
Pars planitis is a chronic form of intermediate uveitis characterized by inflammation of the pars plana, the area between the iris and the retina. First formally described in the 1950s, the condition has evolved from a mysterious ocular ailment into a recognized autoimmune-mediated entity, with 21 individuals currently sharing their lived experiences through the DiseaseMaps.org community.
When was Pars Planitis first identified?
While clinicians had observed peripheral retinal inflammation for decades, the specific entity known as pars planitis was first clearly characterized in 1950 by Dr. Otto Schlaegel. He described it as a syndrome of peripheral uveitis, often noted by the presence of "snowbanking"—exudates along the inferior pars plana. In 1960, Dr. Robert Welch coined the term "pars planitis" to emphasize the anatomical location of the inflammation.
How has the understanding of Pars Planitis evolved?
Historically, pars planitis was often misdiagnosed as ocular tuberculosis or sarcoidosis due to limited diagnostic imaging. As ophthalmology advanced, it became clear that pars planitis is a distinct, idiopathic inflammatory condition rather than an infectious one. The evolution of our understanding has moved from purely clinical observation to advanced immunological profiling, helping doctors distinguish it from other forms of intermediate uveitis.
What major milestones exist in the treatment of Pars Planitis?
The management of pars planitis has shifted from observation to targeted intervention to prevent vision loss. Key milestones include:
- 1960s-70s: The introduction of systemic corticosteroids as the primary method to control inflammation in pars planitis.
- 1990s: The adoption of regional corticosteroid injections (sub-Tenon or intravitreal) to reduce systemic side effects.
- 2000s-Present: The use of steroid-sparing immunosuppressive agents and biologics for patients who are refractory to traditional steroid therapy.
How has modern technology changed our view of the disease?
Modern imaging, particularly Optical Coherence Tomography (OCT) and fluorescein angiography, has revolutionized the management of pars planitis. These tools allow clinicians to quantify macular edema—the most common cause of vision loss in pars planitis—with microscopic precision, allowing for earlier and more effective treatment adjustments.
Next steps
- Consult a uveitis specialist or a retina specialist to ensure an accurate diagnosis using modern imaging.
- Join the pars planitis community at DiseaseMaps.org to connect with others sharing their treatment journeys.
- Maintain regular follow-ups, as silent inflammation can occur even when vision appears stable.
Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD)
- Orphanet: Portal for rare diseases and orphan drugs
- American Uveitis Society (AUS) clinical guidelines
- PubMed: Historical reviews of intermediate uveitis
